NO20062143L - Tablettformuleringer av venlafaxin med forlenget frigjoring - Google Patents

Tablettformuleringer av venlafaxin med forlenget frigjoring

Info

Publication number
NO20062143L
NO20062143L NO20062143A NO20062143A NO20062143L NO 20062143 L NO20062143 L NO 20062143L NO 20062143 A NO20062143 A NO 20062143A NO 20062143 A NO20062143 A NO 20062143A NO 20062143 L NO20062143 L NO 20062143L
Authority
NO
Norway
Prior art keywords
extended
tablet formulations
release venlafaxine
venlafaxine tablet
release
Prior art date
Application number
NO20062143A
Other languages
English (en)
Inventor
Angela Potts
Michael Rowley
Edward Sims
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20062143L publication Critical patent/NO20062143L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en tablett-doseformulering med forlenget frigjøring av det antidepressive midlet venlafaxin-hydroklorid eller en optisk form derav som har forbedret biotilgjengelighet.
NO20062143A 2003-10-13 2006-05-12 Tablettformuleringer av venlafaxin med forlenget frigjoring NO20062143L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03256439A EP1523981A1 (en) 2003-10-13 2003-10-13 Extended release formulations of venlafaxine
PCT/EP2004/011384 WO2005039555A1 (en) 2003-10-13 2004-10-12 Extended release tablet formulations of venlafaxine

Publications (1)

Publication Number Publication Date
NO20062143L true NO20062143L (no) 2006-07-07

Family

ID=34354597

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062143A NO20062143L (no) 2003-10-13 2006-05-12 Tablettformuleringer av venlafaxin med forlenget frigjoring

Country Status (15)

Country Link
US (1) US20050136109A1 (no)
EP (2) EP1523981A1 (no)
KR (1) KR20060118481A (no)
CN (1) CN1889939A (no)
AT (1) ATE409031T1 (no)
AU (1) AU2004283439A1 (no)
CA (1) CA2546203A1 (no)
CO (1) CO5690567A2 (no)
DE (1) DE602004016761D1 (no)
DK (1) DK1677776T3 (no)
EC (1) ECSP066564A (no)
ES (1) ES2313059T3 (no)
NO (1) NO20062143L (no)
WO (1) WO2005039555A1 (no)
ZA (1) ZA200603822B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1476138T1 (sl) * 2002-02-21 2012-07-31 Valeant Internat Barbados Srl Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
WO2004047718A2 (en) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
DE60309565T3 (de) 2003-05-02 2015-01-15 Dexcel Ltd. Tablettenzubereitung mit verlängerter Freisetzung von Venlafaxin
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
ES2606395T3 (es) 2008-04-18 2017-03-23 Intec Pharma Ltd. Administración de fármacos gastrorretentivos para carbidopa/levodopa
ES2562925T3 (es) 2008-12-04 2016-03-09 Intec Pharma Ltd. Sistema de administración de fármaco gastrorretentivo de zaleplón
EP2726066B1 (en) * 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosage forms of amphetamine for oral administration
CN109771380A (zh) * 2017-11-10 2019-05-21 连云港恒运药业有限公司 去甲文拉法辛盐酸盐药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
AU2003226751A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Low water-soluble venlafaxine salts
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
WO2003103603A2 (en) * 2002-06-10 2003-12-18 Wyeth Novel formate salt of o-desmethyl-venlafaxine

Also Published As

Publication number Publication date
ECSP066564A (es) 2006-10-17
DE602004016761D1 (de) 2008-11-06
EP1677776A1 (en) 2006-07-12
CA2546203A1 (en) 2005-05-06
US20050136109A1 (en) 2005-06-23
DK1677776T3 (da) 2009-01-19
ZA200603822B (en) 2008-05-28
ES2313059T3 (es) 2009-03-01
CN1889939A (zh) 2007-01-03
AU2004283439A1 (en) 2005-05-06
ATE409031T1 (de) 2008-10-15
WO2005039555A1 (en) 2005-05-06
KR20060118481A (ko) 2006-11-23
EP1523981A1 (en) 2005-04-20
EP1677776B1 (en) 2008-09-24
CO5690567A2 (es) 2006-10-31

Similar Documents

Publication Publication Date Title
NO20062143L (no) Tablettformuleringer av venlafaxin med forlenget frigjoring
ATE454138T1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
UY30460A1 (es) Compuestos terapéuticos
ECSP088296A (es) Compuestos terapéuticos
CY1106929T1 (el) Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης
CR9609A (es) Formulaciones de una sal de bupropion de liberacion modificada
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
DE602005027540D1 (de) Feste formulierungen von ospemifen
NO20043367L (no) Oralt farmasoytisk preparat
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
MA31430B1 (fr) Formulation a liberation prolongee de nevirapine
BRPI0410044B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
DK1778623T3 (da) Derivater af 1-phenylalkancarboxylsyrer til behandling af neurodegenerative sygdomme
ATE352305T1 (de) Stabile pharmazeutische zusammensetzungen mit desloratadine
ATE389405T1 (de) Fexofenadine hydrochlorid polymorph
NO331227B1 (no) Lineaere basiske forbindelser som har NK-2 antagonistaktivitet, farmasoytiske formuleringer derav og anvendelse av samme for fremstilling av farmasoytiske formuleringer